Skip to main content
ACRUX LIMITED logo

ACRUX LIMITED — Investor Relations & Filings

Ticker · ACR ISIN · AU000000ACR3 LEI · 529900XV9111G3SMCP21 ASX Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2021-09-14 Share Issue/Capital Cha…
Country AU Australia
Listing ASX ACR

About ACRUX LIMITED

https://www.acrux.com.au

Acrux Limited focuses on the development and commercialization of topical and transdermal drug delivery products. The company utilizes proprietary technology platforms to create a pipeline of generic and specialty pharmaceutical products, including creams, gels, ointments, and metered-dose sprays. It specializes in the formulation of complex topical medicines, leveraging expertise in skin penetration and drug delivery systems to improve patient compliance and therapeutic outcomes. The business model involves the internal development of products through to regulatory submission and subsequent commercialization via strategic partnerships. The company maintains a diverse portfolio targeting various therapeutic areas, with a significant emphasis on meeting regulatory requirements for international markets.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - ACR 6 pages 27.1KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities previously issued under an employee incentive scheme where transfer restrictions have ceased. It details the number of securities to be quoted, the type of securities, issue dates, and the resulting issued capital after quotation. This is a formal announcement related to the listing or quotation of securities on the ASX, specifically concerning shares becoming freely tradable after restrictions end. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of Share Issue/Capital Change (SHA) because it announces a change in the capital structure due to securities becoming quoted.
2021-09-14 English
Appendix 3Y - Ross Dobinson 2 pages 215.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, nature of the change, and dates. This is a clear report of personal share transactions by a company director. The document length is 3867 characters, which is consistent with a detailed director's dealing notice rather than a brief announcement or other report type. Therefore, this document fits the definition of 'Director's Dealing' (DIRS).
2021-09-14 English
Acrux's fifth generic dossier accepted by FDA for review 2 pages 200.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 13 September 2021 announcing that the FDA has accepted Acrux's ANDA (Abbreviated New Drug Application) for review. It is a corporate announcement about a regulatory milestone related to product development and FDA review acceptance. The document does not contain financial statements, detailed financial performance, or comprehensive report data. It is not a full annual or interim report, nor is it a call transcript or management report. It is a capital/financing update type announcement related to regulatory approval progress for a product, which fits best under Capital/Financing Update (CAP) as it relates to the company's product pipeline and potential market launch impacting capital and financing outlook. The document length is short (3148 characters) and is a standalone announcement, not a report publication notice or certification. Therefore, the best classification is CAP with high confidence.
2021-09-12 English
Acrux Investor Presentation - September 2021 13 pages 972.5KB
Investor Presentation Classification · 95% confidence The document is titled 'ACRUX INVESTOR PRESENTATION (ASX: ACR)' and dated September 2021. It contains forward-looking statements, business overview, product pipeline, market analysis, financial highlights including profit and loss and cash flow summaries, and investment opportunity details. The content is structured as a presentation with slides, images, and bullet points focusing on company strategy, product development, market positioning, and financial performance. There is no indication that this is a formal annual or quarterly report, audit report, or regulatory filing. The document is clearly a detailed presentation aimed at investors, consistent with an Investor Presentation. The length (12,280 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2021-09-01 English
US Launch - Testosterone Topical Solution 1 page 20
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 26 August 2021 about the launch of a pharmaceutical product (Testosterone Topical Solution USP) by the company's licensee in the US market. It includes background information on licensing and FDA approval, market size, and a statement from the CEO. There are no financial statements, regulatory filings, or detailed financial data. The document is short (2128 characters) and serves as a product launch announcement rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is a general regulatory announcement or company update, which falls under Regulatory Filings (RNS).
2021-08-25 English
Appendix 4E and Financial Report 54 pages 1.2MB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E - Preliminary Financial Report Results for announcement to the market' and includes detailed financial data for the year ended 30 June 2021. It contains a Chairman's Letter, CEO and Managing Director's Report, Directors' Report, Auditor's Independence Declaration, full Financial Report, Directors' Declaration, Independent Auditor's Report, and other comprehensive sections typical of a full annual report. The presence of audited financial statements and detailed management commentary confirms this is a full Annual Report. The document length (15,000 characters) and content depth exclude it from being a mere announcement or summary. Therefore, the document is classified as an Annual Report (10-K equivalent). FY 2021
2021-08-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.